These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 39244290)

  • 1. Updates in the Management of Advanced Nonmelanoma Skin Cancer.
    Yan F; Schmalbach CE
    Surg Oncol Clin N Am; 2024 Oct; 33(4):723-733. PubMed ID: 39244290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Landmark Series: Non-melanoma Skin Cancers.
    Lee AY; Berman RS
    Ann Surg Oncol; 2020 Jan; 27(1):22-27. PubMed ID: 31549317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
    Ascierto PA; Schadendorf D
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
    Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
    Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.
    Lessans S; O'Connell KA; Choe J
    Curr Oncol Rep; 2024 Sep; 26(9):1120-1133. PubMed ID: 38954315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes.
    Shalhout SZ; Kaufman HL; Emerick KS; Miller DM
    Clin Cancer Res; 2022 Jun; 28(11):2211-2220. PubMed ID: 35121622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.
    Sol S; Boncimino F; Todorova K; Waszyn SE; Mandinova A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
    Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
    Villani A; Potestio L; Fabbrocini G; Scalvenzi M
    Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous malignancy of the head and neck.
    Mydlarz WK; Weber RS; Kupferman ME
    Surg Oncol Clin N Am; 2015 Jul; 24(3):593-613. PubMed ID: 25979402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Where do we stand with immunotherapy for nonmelanoma skin cancers in the curative setting?
    Alberti A; Gurizzan C; Baggi A; Bossi P
    Curr Opin Otolaryngol Head Neck Surg; 2024 Apr; 32(2):89-95. PubMed ID: 37997885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy.
    Hall ET; Fernandez-Lopez E; Silk AW; Dummer R; Bhatia S
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32207669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal treatment of unresectable nonmelanoma skin cancers.
    Olencki T
    J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):789-92. PubMed ID: 24853218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
    Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
    [No Abstract]   [Full Text] [Related]  

  • 16. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Hernández-Guerrero T; Doger B; Moreno V
    Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Libtayo
    Gupta AK; Mann A; Vincent K; Abramovits W
    Skinmed; 2024; 22(2):138-143. PubMed ID: 39090000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer.
    Aboul-Fettouh N; Kubicki SL; Chen L; Silapunt S; Migden MR
    Dermatol Clin; 2023 Jan; 41(1):23-37. PubMed ID: 36410980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Therapies for Advanced Basal Cell and Cutaneous Squamous Cell Carcinomas: Novel Targeted Therapies and Immunotherapies.
    Krišto M; Šitum M; Čeović R
    Acta Dermatovenerol Croat; 2020 Aug; 28(2):80-92. PubMed ID: 32876033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines.
    Newlands C; Currie R; Memon A; Whitaker S; Woolford T
    J Laryngol Otol; 2016 May; 130(S2):S125-S132. PubMed ID: 27841126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.